AXQ Capital’s Edwards Lifesciences EW Stock Holding History

AXQ Capital’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-22,778	Closed	-$1.5M	–	500
2024 Q3	$1.5M	Buy	+22,778	New	+$1.65M	0.45%	47
2024 Q1	–	Sell	-10,500	Closed	-$801K	–	702
2023 Q4	$801K	Buy	+10,500	New	+$731K	0.21%	170

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

AXQ Capital's EW Position: Q4 2024 in Review

AXQ Capital sold out of Edwards Lifesciences (EW) in Q4 2024, closing a stake of 22,778 shares — an estimated $1.5M sold.

AXQ Capital first reported a position in EW in Q4 2023 and held it in 2 quarters. The position peaked at $1.5M in Q3 2024. 1,229 funds tracked by Wall St. Rank hold EW as of Q4 2024.

AXQ Capital reported no remaining Edwards Lifesciences position as of Q4 2024 after selling out during the quarter.
AXQ Capital sold 22,778 Edwards Lifesciences shares in Q4 2024, an estimated $1.5M.
AXQ Capital first reported a position in Edwards Lifesciences in Q4 2023 and held it in 2 quarters.
AXQ Capital's Edwards Lifesciences position peaked at $1.5M in Q3 2024.
1,229 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2024.

Based on AXQ Capital's 13F filing for Q4 2024, filed 11 Feb 2025.